Stay updated with breaking news from Sumanta Pal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.
Responses to 'special drug' zanzalintinib in cabozantinib-exposed and unexposed patients
– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in...
First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...
Transformations in the Life Sciences is the focus of the second season of the MedCity Pivot Podcast. My personal journey as a caregiver of a cancer patient made me choose Dr. Sumanta Pal, co-director of the City of Hope's Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet.